/EINPresswire.com/ -- BERKELEY, CA--(Marketwired - January 06, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) will host a conference call and webcast tomorrow morning, January 7, 2016, at 8:30 a.m. EST. Management looks forward to reviewing top-line clinical data from its Phase 3 HEPLISAV-B trial, HBV-23.

To access the conference call by phone, please dial (877) 479-1857 from the United States and Canada or (503) 343-6309 internationally. The conference ID is 16055092. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through January 13, 2016, and may be accessed by dialing (855) 859-2056 from the United States and Canada or (800) 585-8367 internationally. The replay passcode is 16055092.

To access the live and subsequently archived webcast of the conference call, please go to the Company's website at http://www.dynavax.com and go to "Events & Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit www.dynavax.com.

Contact:
Jennifer Williams
Cook Williams Communications, Inc.
360-668-3614
Email contact

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.